Jeremy T. Larsen

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

Jeremy T. Larsen, Shaji Kumar, Angela Dispenzieri et al. · Leukemia · 2012 · 235 citations

Medicine, Hematology, Oncology +10

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Simon J. Harrison, Monique C. Minnema, Hans C. Lee et al. · Blood · 2020 · 112 citations

Life Sciences, Hematology, Immunology +17

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Sagar Lonial, Rakesh Popat, Cyrille Hulin et al. · The Lancet Haematology · 2022 · 92 citations · Full text

Medicine, Hematology, Oncology +11

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

Praful Ravi, Shaji Kumar, Jeremy T. Larsen et al. · Blood Cancer Journal · 2016 · 73 citations · Full text

Medicine, Hematology, Oncology +13

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Magdalini Migkou, Manisha Bhutani et al. · Blood · 2020 · 57 citations

Medicine, Clinical Sciences, Oncology +10